Eton Pharmaceuticals, Inc. cotiza a 53.33 USD y tiene una capitalización bursátil de $1.5B. En los últimos 12 meses ha facturado $106M con un margen de flujo de caja libre del 12.8%. Cotiza a 103.5 veces su flujo de caja libre (P/FCF) y a un PER de 120.1. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency;…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $0.14 | $0.19 |
| Estimado | $0.37 | $0.19 | $0.14 | $0.20 |
| Sorpresa | — | — | +0.0% | -5.0% |
| Métrica | ETON | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 53.5% | 57.0% | -3.6% |
| Operating Margin | -1.1% | -38.6% | +37.6% |
| Net Margin | -5.8% | -33.6% | +27.8% |
| FCF Margin | 12.8% | -13.9% | +26.6% |
| ROE | -17.6% | -40.4% | +22.8% |
| ROA | -5.0% | -32.0% | +27.0% |
| Current Ratio | 1.57 | 2.84 | -1.27 |
| Debt / Equity | 0.83 | 0.28 | +0.55 |